Difference between revisions of "NF-kappa-B inhibitor alpha"
| Line 30: | Line 30: | ||
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
| − | | | + | | PRDGL''KK''ERLLD |
| + | LHSIL''K''ATNYN | ||
| + | PSTRI''QQ''QLGQL | ||
| + | DCVFGG''Q''RLTL | ||
|- | |- | ||
| Structure | | Structure | ||
Revision as of 12:26, 23 July 2007
| Template:Infobox header| NF-kappa-B inhibitor alpha | |
|---|---|
| NF-kappa-B inhibitor alpha | |
| Substrate peptide name | NF-kappa-B inhibitor alpha |
| Synonyms | NF-kappa-B inhibitor alpha
I-kappa-B-alpha |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol |
| Swissprot ID | P25963 |
| Reactive glutamines | Q266, Q267, Q313 |
| Reactive lysines | K21, K22, K177 |
| Substrate sequence | PRDGLKKERLLD
LHSILKATNYN PSTRIQQQLGQL DCVFGGQRLTL |
| Structure | 2BTF |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:16987813 |
| Notes | |
| Template:Infobox header | | |
